Key facts
- Zhiyi Biotechnology’s last known valuation is $676.3M (Jul 2022).
- It has raised $107.7M; the latest was Later Stage VC in Apr 2026.
- Notable investors include Shenzhen Capital Group, Korea Investment Partners, Sinovation Ventures, Guangdong Technology Financial Group, Cathay Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Zhiyi Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Zhiyi Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zhiyi Biotechnology
Developer of live biotherapeutics designed to advance microbiome-based drug discovery and treatment development. The company offers research microbial cultures and strains to develop effective treatments, is focused on unmet medical needs, and is dedicated to developing accessible drugs to benefit more patients, enabling healthcare professionals to prescribe better medicine.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2013
- Employees
- 150
- Website
- zypharm.com.cn/
- Ownership
- Privately Held (backing)
Zhiyi Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zhiyi Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zhiyi Biotechnology in its N-PORT filings yet. We sweep new filings monthly.